Development of novel drugs for pancreatic cancer targeting Glypican-1

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K16960
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: Kochi University
• Principal Investigator: Uemura Sunao 高知大学, 医学部, 客員助教 (80566191)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 膵癌 / GPC-1

Outline of Final Research Achievements

Pancreatic ductal adenocarcinoma (PDAC) is a stroma-rich cancer. GPC1-ADC(MMAE) exhibited potent and unique antitumor activity in GPC1-positive PDAC PDX models, which suggests that GPC1 is a novel therapeutic target in PDAC and other stromal GPC1-positive solid tumors. These findings show that targeting GPC1 on CAF using GPC1-ADC(MMAE) is a useful approach in case of stroma-rich tumors such as PDAC.

Free Research Field

肝胆膵外科

Academic Significance and Societal Importance of the Research Achievements

GPC1 が、膵癌患者における間質障壁による不十分な薬物送達を克服できる抗体の有望な標的である可能性を示した。これらの結果は、今後膵癌治療の選択肢を広げる重要な知見であると考えられる。